Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital

Fineline Cube Jan 14, 2026
Company Deals

Iktos and Servier Forge EUR 1 Billion+ AI Drug Discovery Collaboration

Fineline Cube Jan 14, 2026
Company Deals

Hisoar Pharma Invests RMB 150 Million in Wanbangde’s WP205 for ALS, Securing 15 % Global Revenue Share

Fineline Cube Jan 13, 2026
Company Deals

Bayer AG Acquires Cardiac Amyloidosis Imaging Tracers from Attralus, Including Phase III AT‑01 with FDA Breakthrough Designation

Fineline Cube Jan 13, 2026
Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Fineline Cube Jan 13, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

Haichang Biotech’s HC016 Receives FDA Orphan Drug Designation for Osteosarcoma

Fineline Cube Jan 14, 2026
Company Drug

Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes

Fineline Cube Jan 13, 2026
Company Deals

Servier and HUST Forge Partnership to Cultivate Innovative Therapies through SHINEDocs Program

Fineline Cube Oct 17, 2024

French pharmaceutical company Servier has joined forces with Huazhong University of Science and Technology (HUST),...

Company Drug

Innovent Biologics’ Picankibart Achieves Positive Results in Phase II UC Study

Fineline Cube Oct 17, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...

Company

Bayer AG Launches China Innovation Hub to Boost Local R&D and Global Integration

Fineline Cube Oct 17, 2024

Bayer AG (ETR: BAYN), a German multinational pharmaceutical and life sciences giant, has announced the...

Company Deals

Lexicon Pharmaceuticals Strikes Licensing Deal with Viatris for Global Expansion of Sotagliflozin

Fineline Cube Oct 17, 2024

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) has entered into a licensing agreement with Viatris Inc. (NASDAQ:...

Company Drug

Johnson & Johnson’s Nipocalimab Shows Promise in Treating Adolescent Myasthenia Gravis in Phase II/III Trial

Fineline Cube Oct 17, 2024

Johnson & Johnson (J&J, NYSE: JNJ), a US pharmaceutical giant, has reported encouraging outcomes from...

Policy / Regulatory

NHSA Standardizes NRDL Drug Purchases to Combat Prescription Fraud

Fineline Cube Oct 17, 2024

The National Healthcare Security Administration (NHSA) has issued a notification aimed at standardizing the management...

Policy / Regulatory

Shanxi Province Announces Historic Drug Procurement Batch with 81 Products for 2024

Fineline Cube Oct 17, 2024

On October 16, 2024, Shanxi Province’s drug procurement platform announced a notice regarding the submission...

Company Drug

Alphamab Oncology and CSPC Pharma’s KN026 Phase III Trial for Breast Cancer Gets NMPA Approval

Fineline Cube Oct 17, 2024

Alphamab Oncology (HKG: 9966) and CSPC Pharma (HKG: 1093) have jointly announced that their Phase...

Company Deals

Boehringer Ingelheim Pledges USD 5 Million to WHO Foundation for Global Healthcare Advancement

Fineline Cube Oct 16, 2024

Boehringer Ingelheim (BI), a leading German pharmaceutical company, has joined forces with the World Health...

Company

J&J Reports Q3 2024 Revenue Growth, Raises Full-Year Guidance on Strong Pipeline Progress

Fineline Cube Oct 16, 2024

Johnson & Johnson (J&J, NYSE: JNJ) has released its financial report for the third quarter...

Company Drug

Shanghai Junshi Biosciences’ Toripalimab Wins Marketing Approvals in India and Hong Kong for Nasopharyngeal Carcinoma

Fineline Cube Oct 16, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biotech company based in...

Company

Eli Lilly Launches Medical Innovation Center and Gateway Labs in Beijing to Accelerate Clinical Trials and R&D

Fineline Cube Oct 16, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical corporation in the US, has announced...

Company Drug

Jiangsu Hengrui Resubmits Application for Camrelizumab Combo in HCC to FDA

Fineline Cube Oct 16, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company based in China, has...

Company Drug

Innovec Biotherapeutics’ IVB103 Gene Therapy for nAMD Receives Clinical Trial Approval from China’s CDE

Fineline Cube Oct 16, 2024

Beijing InnoVec Biotherapeutics Inc., a leading gene therapy company based in China, has announced that...

Company Drug

Aficamten Market Filing Accepted by China’s CDE for Hypertrophic Cardiomyopathy Treatment

Fineline Cube Oct 16, 2024

CORXEL, formerly known as Ji Xing Pharmaceuticals and Cytokinetics Inc (CYTK, NASDAQ: CYTK) have achieved...

Company Drug

Jiangsu Hengrui’s Hetrombopag Olamine Receives NMPA Review for Severe Aplastic Anemia Indication

Fineline Cube Oct 16, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

Hinova Pharmaceuticals Gets NMPA Green Light for HP568 Clinical Study in Breast Cancer

Fineline Cube Oct 16, 2024

Hinova Pharmaceuticals Inc. (SHA: 688302), a biotech firm based in Chengdu, has announced that it...

Company Deals

Boehringer Ingelheim Partners with Circle Pharma to Develop First-in-Class Cyclin Inhibitor

Fineline Cube Oct 16, 2024

Boehringer Ingelheim (BI), a leading German pharmaceutical company, has announced a research collaboration and license...

Company Deals

TenNor Therapeutics Secures USD 42.16 Million in Series E Financing for Antibacterial Pipeline

Fineline Cube Oct 16, 2024

TenNor Therapeutics, a clinical-stage pharmaceutical company based in China, has announced the successful completion of...

Company Drug

Huadong Medicine Gets NMPA Green Light for BCMA-Targeted ADC HDM2027 Phase I/IIa Study

Fineline Cube Oct 16, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced that it has...

Posts pagination

1 … 226 227 228 … 609

Recent updates

  • Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital
  • Haichang Biotech’s HC016 Receives FDA Orphan Drug Designation for Osteosarcoma
  • Iktos and Servier Forge EUR 1 Billion+ AI Drug Discovery Collaboration
  • Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes
  • CSPC’s Prusogliptin/Metformin FDC NDA Accepted by NMPA for Type 2 Diabetes, Targeting 60 M Underserved Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital

Company Drug

Haichang Biotech’s HC016 Receives FDA Orphan Drug Designation for Osteosarcoma

Company Deals

Iktos and Servier Forge EUR 1 Billion+ AI Drug Discovery Collaboration

Company Drug

Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.